

More than
37 YEARS OF
HEALTH CARE

“ Taking the Legacy of
Ayurveda ahead,
Scientifically...”



AIMIL

PHARMACEUTICALS (INDIA) LTD.



ANNUAL REPORT

2020 - 2021





INDEPENDENT AUDITORS' REPORT

TO,

THE MEMBERS OF AIMIL PHARMACEUTICALS (INDIA) LIMITED

Report on the Financial Statements

We have audited the accompanying financial statements of **AIMIL PHARMACEUTICALS (INDIA) LIMITED**, which comprise the Balance Sheet as at **31/03/2021**, the Statement of Profit and Loss, the **cash flow statement** for the year then ended, and a summary of the significant accounting policies and other explanatory information.

Auditor's Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at **31/03/2021**, and its **Profit and it's cash flows** for the year ended on that date.

Basis for Opinion


We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to notes to the financial results which describes the uncertainties and the impact of Covid-19 pandemic on the Company's operations and results as assessed by the management. Our opinion is not modified in respect of this matter.

Responsibility of Management and Those Charged with Governance (TCWG)

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.



Page No. 1

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists.


Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



Report on Other Legal and Regulatory Requirements


As required by the Companies (Auditors' Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub section (11) of section 143 of the Companies Act, 2013. We give in the Annexure A statements on the matters specified in paragraphs 3 and 4 of the order, to the extent applicable.

As required by Section 143 (3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and **the cash flow statement** dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on **31/03/2021** taken on record by the Board of Directors, none of the directors is disqualified as **31/03/2021** from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "**Annexure B**".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
 - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

Date : 01.11.2021
Place : DELHI

FOR AMBANI AND ASSOCIATES LLP
(Chartered Accountants)
Reg No. : 0016923N


HITESH AMBANI
Designated Partner

M.No. : 506267
UDIN : 21506267AAAAQC3105



ANNEXURE - A

Reports under The Companies (Auditor's Report) Order, 2016 (CARO 2016) for the year ended on 31st March 2021

(i) In Respect of Fixed Assets

(a) The company has maintained proper records showing full particulars including quantitative details and situation of fixed assets.

(b) Fixed assets have been physically verified by the management at reasonable intervals; No material discrepancies were noticed on such verification.

(c) Based on our audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to information and explanations given by the management, the title deeds of immovable properties included in property, plant and equipment are held in the name of the Company.

(ii) In Respect of Inventories

Physical verification of inventory has been conducted at reasonable intervals by the management.

(iii) Compliance under section 189 of The Companies Act, 2013

The company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained u/s 189 of the companies Act-2013.

(a) In our opinion and according to the information and explanations given to us. The rate of interest and other terms and conditions for such loans are not prima facie prejudicial to the interest to the company.

(b) In respect of loans granted, repayment of the principal amount is as stipulated and payment of interest have been regular.

(c) There is no overdue amount of loans granted to companies, firms or other parties listed in the register maintained under section 189 of the companies Act, 2013.

(iv) Compliance under section 185 and 186 of The Companies Act , 2013

While doing transaction for loans, investments, guarantees, and security provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

(v) Compliance under section 73 to 76 of The Companies Act, 2013 and Rules framed thereunder while accepting Deposits

The company has not accepted any Deposits.

(vi) Maintenance of cost records

We have reviewed the books of accounts relating to materials, labour and other items of cost maintained by the company pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (1) of section 148 of the Companies Act, 2013 and we are of the opinion that prima facie the prescribed accounts and records have been made and maintained.



(vii) Deposit of Statutory Dues

statutory dues including provident fund, employees state insurance, income tax, sales tax, wealth tax, service tax, customs duty, excise duty, cess have not generally been regularly deposited with the appropriate authorities though the delays in deposit have not been serious.

(viii) Repayment of Loans and Borrowings

The company has not defaulted in repayment of dues to financial institution, or a bank.

(ix) Utilization of Money Raised by Public Offers and Term Loan For which they Raised

The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under Clause 3 (ix) of the Order is not applicable to the Company.

(x) Reporting of Fraud During the Year

Based on our audit procedures and the information and explanation made available to us no such fraud noticed or reported during the year.

(xi) Managerial Remuneration

Managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act.

(xii) Compliance by Nidhi Company Regarding Net Owned Fund to Deposits Ratio

The Company is not a Nidhi company and hence, reporting under Clause 3 (xii) of the Order is not applicable to the Company.

(xiii) Related party compliance with Section 177 and 188 of companies Act - 2013

Yes, All transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the applicable accounting standards.

(xiv) Compliance under section 42 of Companies Act - 2013 regarding Private placement of Shares or Debentures

No, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review.

(xv) Compliance under section 192 of Companies Act – 2013

The company has not entered into any non-cash transactions with directors or persons connected with him.

(xvi) Requirement of Registration under 45-IA of Reserve Bank of India Act, 1934

The company is not required to be registered under section 45-IA of the Reserve Bank of India Act.

Place : DELHI

Date : 01.11.2021

FOR AMBANI AND ASSOCIATES LLP

(Chartered Accountants)


Reg No. :016923N


HITESH AMBANI

(Designated Partner)

Membership No : 506267

UDIN : 21506267AAAAQC3105



“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of AIMIL PHARMACEUTICALS (INDIA) LIMITED.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013.

We have audited the internal financial controls over financial reporting of AIMIL PHARMACEUTICALS (INDIA) LIMITED as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility


Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and operating effectiveness of internal control based on the assessed risk. The procedures selected depend upon on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.



Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

Date : 01.11.2021
Place : DELHI

FOR AMBANI AND ASSOCIATES LLP
(Chartered Accountants)
Reg No. :0016923N


HITESH AMBANI
Designated Partner

M.No. : 506267
UDIN : 21506267AAAAQC3105



"जय माता दी"



AIMIL PHARMACEUTICALS (INDIA) LIMITED

2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008

CIN - U24231DL1984PLC019461

BALANCE SHEET AS AT 31st MARCH, 2021

	PARTICULARS	SCH.	AS AT 31.03.2021	AS AT 31.03.2020
I	EQUITY AND LIABILITIES			
1	SHAREHOLDER'S FUNDS			
	(a) Share Capital	3	12,50,56,000	13,17,56,000
	(b) Reserves and Surplus	4	20,60,12,105	18,36,98,628
	(c) Money received against share warrants		-	-
2	SHARE APPLICATION MONEY PENDING ALLOTMENT		-	-
3	NON CURRENT LIABILITIES			
	(a) Long-Term Borrowings	5	45,84,21,242	46,26,18,628
	(b) Deferred Tax Liabilities (Net)	6	47,93,232	24,25,299
	(c) Other Long Term Liabilities		-	-
	(d) Long Term Provisions		-	-
4	CURRENT LIABILITIES			
	(a) Short-Term Borrowings	7	43,81,76,202	42,44,09,185
	(b) Trade Payables	8	33,14,63,635	29,10,74,318
	(c) Other Current Liabilities	9	11,75,69,947	8,45,66,392
	(d) Short Term Provisions	10	11,99,29,169	12,71,16,483
	TOTAL Rs...		1,80,14,21,532	1,70,76,64,934
II	ASSETS			
1	PROPERTY, PLANT & EQUIPMENTS AND INTANGIBLE ASSETS			
	(a) Property, Plant & Equipments :	11		
	(i) Tangible Assets		25,14,16,862	23,07,69,877
	(ii) Intangible Assets		1,68,079	1,68,079
	(iii) Capital work in Progress		-	-
	(iv) Intangible Assets under development		-	-
	(b) Non Current Investments		-	-
	(c) Deferred Tax Assets (Net)		-	-
	(d) Long-Term Loans and Advances	12	16,30,50,000	16,30,50,000
	(e) Other Non-Current Assets		-	-
2	CURRENT ASSETS			
	(a) Current Investments		-	-
	(b) Inventories	13	31,62,58,928	26,19,24,163
	(c) Trade Receivables	14	1,02,96,92,081	1,00,64,47,729
	(d) Cash and Cash Equivalents	15	65,57,280	1,57,18,942
	(e) Short-Term Loans and Advances	16	3,42,78,302	2,95,86,143
	(f) Other Current Assets		-	-
	TOTAL Rs...		1,80,14,21,532	1,70,76,64,934

SIGNIFICANT ACCOUNTING POLICIES

ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL STATEMENTS

1

2

As Per Our Report of Even Date Attached

For Ambani & Associates LLP

Chartered Accountants

FRN - 116923N

Hitesh Ambani

Designated Partner
(MN-506267)



For and on behalf of the Board

Kanwal Kumar Sharma

Kanwal Kumar Sharma
(Managing Director)
DIN - 00526387

B-34, Surya Enclave, New
Multan Nagar, Delhi-56

Pankaj Marwaha

Pankaj Marwaha
(Director - Marketing)
DIN - 00526342

1313, Sector-19 B,
Chandigarh-160019

Ram Sawroop Sharma
Ram Sawroop Sharma
(Chief Financial Officer)

Gaurav Agarwal
Gaurav Agarwal
(Company Secretary)

Place: New Delhi

Date: 01st November 2021

UDIN: 21506267AAAAQC3105



AIMIL PHARMACEUTICALS (INDIA) LIMITED
2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008
CIN - U24231DL1984PLC019461

PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31st March, 2021

PARTICULARS	SCH.	YEAR ENDED 31.03.2021	YEAR ENDED 31.03.2020
INCOME			
Revenue from operations (gross)	17	4,02,31,81,049	2,91,76,02,509
I Revenue from operations (net)		4,02,31,81,049	2,91,76,02,509
II Other income	18	48,18,131	38,94,874
III. Total Revenue		4,02,79,99,180	2,92,14,97,383
IV. EXPENDITURE			
Cost of Materials Consumed	19	76,36,18,250	43,57,91,835
Purchases of Stock -in-Trade		16,57,48,298	48,74,87,258
Changes in Inventories of Finished Goods and Stock-in-Process	20	-2,28,39,493	-4,51,76,333
Employee Benefits Expense	21	88,90,29,534	75,90,48,786
Other Expenses	22	2,04,96,85,772	1,11,24,51,525
Finance Costs	23	11,03,54,433	11,27,68,718
Depreciation		3,63,68,475	3,72,43,019
Total Expenses		3,99,19,65,270	2,89,96,14,807
V. Profit Before exceptional and extraordinary items and tax (III - IV)		3,60,33,909	2,18,82,576
VI. Exceptional Items		-	-
VII. Profit Before extraordinary items and tax (V - VI)		3,60,33,909	2,18,82,576
VIII. Extraordinary Items		-	-
IX Profit before Tax (VII-VIII)		3,60,33,909	2,18,82,576
X Tax Expenses			
(1) Current Tax		94,88,500	60,00,000
(2) Deferred tax		23,67,933	-9,24,226
Total Tax Expenses		1,18,56,432	50,75,774
XI Profit (Loss) for the period from continuing operations (VII-VIII)		2,41,77,477	1,68,06,802
XII Profit/(loss) from discontinuing operations		-	-
XIII Tax expense of discontinuing operations		-	-
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-
XV Profit (Loss) for the period (XI + XIV)		2,41,77,477	1,68,06,802
XVI Earnings per equity share:			
(1) Basic		29.57	20.56
(2) Diluted			

SIGNIFICANT ACCOUNTING POLICIES

ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL STATEMENTS

As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

Hitesh Ambani
Designated Partner
(MN-506267)

For and on behalf of the Board

Kanwal Kumar Sharma
Kanwal Kumar Sharma
(Managing Director)
DIN - 00526387
B-34, Surya Enclave, New
Multan Nagar, Delhi-56

Pankaj Marwaha
Pankaj Marwaha
(Director - Marketing)
DIN - 00526342
1313, Sector-19 B,
Chandigarh-160019

Ram Sawroop Sharma
Ram Sawroop Sharma
(Chief Financial Officer)

Gaurav Agarwal
Gaurav Agarwal
(Company Secretary)

Place: New Delhi

Date: 01st November 2021

UDIN: 21506267AAAAQC3105



AIMIL PHARMACEUTICALS (INDIA) LIMITED

Particulars	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 4 : RESERVES AND SURPLUS		
a. Capital Reserves		
Opening Balance	-	-
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	-	-
b. Capital Redemption Reserve		
Opening Balance	-	-
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	-	-
c. Securities Premium Account		
Opening Balance	64,80,000	64,80,000
Add : Securities premium credited on Share issue	-	-
Less : Premium Utilised for various reasons	-	-
Premium on Redemption of Debentures	-	-
For Issuing Bonus Shares	-	-
Closing Balance	64,80,000	64,80,000
d. Debenture Redemption Reserve		
Opening Balance	-	-
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	-	-
e. Revaluation Reserve		
Opening Balance	-	-
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	-	-
f. Share Options Outstanding Account		
Opening Balance	-	-
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	-	-
g. Other Reserves (Specify the nature and purpose of each reserve)		
General Reserve		
Opening Balance	5,16,745	5,16,745
(+) Current Year Transfer	-	-
(-) Written Back in Current Year	-	-
Closing Balance	5,16,745	5,16,745
h. Surplus		
Opening balance	17,67,01,883	16,27,88,521
(+) Net Profit/(Net Loss) For the current year	2,41,77,477	1,68,06,802
(+) Transfer from Reserves	-	-
(-) Proposed Dividends	18,64,000	24,00,000
(-) Tax on Dividends	-	4,93,440
(-) Interim Dividends	-	-
(-) Transfer to Reserves	-	-
Closing Balance	19,90,15,360	17,67,01,883
Total	20,60,12,105	18,36,98,628

[Signature]

[Signature]

[Signature]

[Signature]





AIMIL PHARMACEUTICALS (INDIA) LIMITED

Particulars	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 5 : LONG TERM BORROWINGS		
Secured		
(a) Bonds/debentures		
(b) Term loans		
- From Banks (Term Loan)	3,66,76,522	4,86,76,522
(Secured against Plant & Machinery of company and personal guarantee of Directors)		
- From Banks (Vehicles Loan)	97,25,211	1,31,10,211
(Secured against hypothecation of Vehicles)		
- From Other Parties	-	-
(c) Deferred payment liabilities	-	-
(d) Security Deposits	-	-
(e) Loans and advances from related parties	-	-
(f) Long term maturities of finance lease obligations	-	-
(g) Other loans and advances (specify nature)	-	-
In case of continuing default as on the balance sheet date in repayment of loans and		
1. Period of default		
2. Amount		
Unsecured		
(a) Bonds/debentures	-	-
(b) Term loans	-	-
- From Banks		
- From Other Parties/Financial Institutions		
(c) Deferred payment liabilities	-	-
(d) Security Deposits	41,20,19,509	40,08,31,895
(e) Loans and advances from related parties	-	-
(f) Long term maturities of finance lease obligations	-	-
(g) Other loans and advances (Specify nature)	-	-
In case of continuing default as on the balance sheet date in repayment of loans and		
1. Period of default		
2. Amount		
Total	45,84,21,242	46,26,18,628
SCHEDULE - 6 : DEFERRED TAX LIABILITIES		
Deferred Tax Liabilities	47,93,232	24,25,299
	47,93,232	24,25,299

Signature

Signature

Signature

Signature





AIMIL PHARMACEUTICALS (INDIA) LIMITED

Particulars	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 7 : SHORT - TERM BORROWINGS		
Secured		
(a) Loans repayable on demand		
From banks Cash credits Loan (Secured against Hypothecation of stocks, Debtors, including Govt. Bills, equitable mortgage on immovable properties, plant & machinery of existing unit and personal guarantee of Directors, rate of interest charged is 12%)	41,01,93,911	42,44,09,185
From banks (Guaranteed Emergency Credit Line (GECL-Covid -19)) (Secured by Govt., Rate of interest charged is 8%.)	2,79,82,291	-
From other parties (' is guaranteed by Directors)	-	-
Term Loan (Secured By Fixed Assets)	-	-
(b) Loans and advances from related parties (Secured By)	-	-
(of the above, ' is guaranteed by Directors and / or others)	-	-
(c) Security Deposits (Secured By)	-	-
(of the above, ' is guaranteed by Directors and / or others)	-	-
(d) Other loans and advances (specify nature) (Secured By)	-	-
(of the above, ' is guaranteed by Directors and / or others)	-	-
In case of continuing default as on the balance sheet date in repayment of loans and		
1. Period of default		
2. Amount		
Unsecured		
(a) Loans repayable on demand		
from banks	-	-
from other parties (of the above, ' is guaranteed by Directors and / or others)	-	-
(b) Loans and advances from related parties (..... is guaranteed by Directors and / or others)	-	-
(c) Deposits (of the above, ' is guaranteed by Directors and / or others)	-	-
(d) Other loans and advances (Advances from Customer) (' NIL is guaranteed by Directors and / or others)	-	-
In case of continuing default as on the balance sheet date in repayment of loans and		
1. Period of default		
2. Amount		
Total	43,81,76,202	42,44,09,185
SCHEDULE - 8 : TRADE PAYABLES		
Total Outstanding dues to micro and small medium industries *	54,54,528	45,75,437
Total Outstanding dues to Creditors other than micro and small medium industries	32,60,09,107	28,64,98,881
Creditors - Others		
	33,14,63,635	29,10,74,318

* The Ministry of Micro, Small and Medium Enterprises has issued an Office Memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Based on the information available with the management, there are no overdues outstanding to micro and small enterprises as defined under the Micro, Small and Medium Enterprises Development Act, 2006. Further the company has not received any claim for interest from any supplier under the said act.

[Signature]

[Signature]
[Signature]





AIMIL PHARMACEUTICALS (INDIA) LIMITED


Particulars	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 9 : OTHER CURRENT LIABILITIES		
(a) Current maturities of long-term debt		
i) Secured Loans		
- From Banks (Term Loan)	1,20,00,000	40,37,235
- From Banks (Vehicles Loan)	33,85,000	30,47,866
ii) Unsecured Loans		
(b) Current maturities of finance lease obligations	-	-
(c) Interest accrued but not due on borrowings	-	-
(d) Interest accrued and due on borrowings	-	-
(e) Income received in advance	-	-
(f) Unpaid dividends	-	-
(g) Application money received for allotment of securities and due for refund #	-	-
interest accrued on (g) above	-	-
Terms and conditions of shares proposed to be issued:		
Shares to be allotted at Premium		
Date by which shares shall be allotted: _____		
Whether the company has sufficient authorized capital to cover the share capital amount resulting from allotment of shares out of such share application money		
The period overdue from the last date of allotment is _____; reason being		
# All amounts out of Share Application money which are refundable to be shown under this head (non-refundable portion of share application money will form part of 'Share Application Money Pending Allotment' (Balance Sheet)		
(h) Unpaid matured deposits and interest accrued thereon	-	-
(i) Unpaid matured debentures and interest accrued thereon	-	-
(k) Other Payables	10,21,84,947	7,74,81,291
	11,75,69,947	8,45,66,392
SCHEDULE - 10 : SHORT - TERM PROVISIONS		
(a) Provision for employee benefits		
Salary & Reimbursements	9,67,32,592	11,03,24,593
Contribution to ESI/PF	1,04,95,778	1,07,91,890
Gratuity (Funded)	-	-
Leave Encashment (funded)	-	-
Superannuation (funded)	-	-
ESOP /ESOS	-	-
Provision for FBT	-	-
Provision for Tax	-	-
(b) Income Tax Provision	1,27,00,799	60,00,000
	11,99,29,169	12,71,16,483
SCHEDULE - 12 : LONG TERM LOANS AND ADVANCES		
a. Capital Advance		
Secured, considered good	-	-
Unsecured, considered good	-	-
Doubtful	-	-
Less:Provision for doubtful loans and advances	-	-
b. Security Deposits		
Secured, considered good	-	-
Unsecured, considered good	16,30,50,000	16,30,50,000
Doubtful	-	-
Less:Provision for doubtful Debts	-	-
	16,30,50,000	16,30,50,000

[Signature]

[Signature]

[Signature]

[Signature]





AIMIL PHARMACEUTICALS (INDIA) LIMITED

Particulars	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 13 : INVENTORIES (As verified and certified by the management)		
a. Raw Materials and components (Valued at cost or net reliable value, whichever is less) Goods-in transit	7,49,71,909	6,80,27,446
b. Work-in-progress (Valued at cost or net reliable value, whichever is less) Goods-in transit	2,84,40,381	3,29,28,229
c. Finished goods (Valued at cost or net reliable value, whichever is less) Goods-in transit	11,63,47,971 1,39,00,064	10,00,66,659 73,41,883
d. Stock-in-trade (Valued at _____) Goods-in transit	-	-
e. Stores and spares (Valued at _____) Goods-in transit	-	-
f. Loose Tools (Valued at _____) Goods-in transit	-	-
g. Others (Specify nature) Packing Material (Valued at cost or net reliable value, whichever is less) Goods-in transit	8,25,98,603	5,35,59,945
h. Others (Specify nature) Goods in transit	0	0
	31,62,58,928	26,19,24,163
SCHEDULE - 14 : TRADE RECEIVABLES		
Trade receivables outstanding for a period less than six months from the date they are due for payment Secured, considered good Unsecured, considered good Unsecured, considered doubtful Less: Provision for doubtful debts	- - 99,50,20,811 - -	- - 97,21,92,969 - -
Trade receivables outstanding for a period exceeding six months from the date they are due for payment Secured, considered good Unsecured, considered good Unsecured, considered doubtful Less: Provision for doubtful debts	- - 3,46,71,270 - -	- - 3,42,54,760 - -
	1,02,96,92,081	1,00,64,47,729
SCHEDULE - 15 : CASH AND CASH EQUIVALENTS		
i)		
a. Balances with banks	20,53,036	78,26,434
b. Cheques, drafts on hand	-	-
c. Cash on hand	13,89,441	27,82,411
d. Others (Please specify) Bank deposits with less than 12 months maturity	5,00,000	24,95,294
ii) Earmarked Balances (eg/- unpaid dividend accounts)		
iii) Margin money, Security against borrowings, Guarantees, Other Commitments		
iv) Bank deposits with more than 12 months maturity	26,14,803	26,14,803
	65,57,280	1,58,88,942

Dr. S. Srinivasan

Baruah

Debasish

Chand

Page No. 14




AIMIL PHARMACEUTICALS (INDIA) LIMITED

	AS AT 31.03.2021	AS AT 31.03.2020
SCHEDULE - 16 : SHORT - TERM LOANS AND ADVANCES		
a. Loans and advances to related parties (refer note 2)		
Secured, considered good	-	-
Unsecured, considered good	-	-
Doubtful	-	-
Less:Provision for doubtful loans and advances	-	-
b. Others (specify nature)		
Secured, considered good	-	-
Unsecured, considered good	3,42,78,302	2,95,86,143
Doubtful	-	-
Less:Provision for doubtful Debts	-	-
	3,42,78,302	2,95,86,143
SCHEDULE - 17 : REVENUE FROM OPERATIONS		
Domestic Sales	3,94,64,51,391	2,81,82,44,992
Export sales	7,67,29,658	9,93,57,516
	4,02,31,81,049	2,91,76,02,509
SCHEDULE - 18 : OTHER INCOME		
Interest Income	5,25,388	13,02,412
Dividend Income	-	35,000
Net gain /loss on sale of investment	-	-
Miscellaneous Income	42,92,743	25,57,462
Other non-operating income (net of expenses directly attributable to such income):	-	-
	48,18,131	38,94,874
SCHEDULE - 19 : COST OF MATERIALS CONSUMED		
<u>Raw Material Consumed</u>		
Opening Stock	10,09,55,675	9,85,71,498
Add : Purchases during the year	49,81,89,753	24,95,14,740
Less : Closing Stock	10,34,12,290	10,09,55,675
Less : Expenses incurred on R & D	1,48,71,994	74,13,917
Raw Material Consumed	48,08,61,144	23,97,16,646
<u>Packing Material Consumed</u>		
Opening Stock	5,35,59,945	4,16,40,759
Add : Purchases during the year	31,17,95,764	20,79,94,375
Less : Closing Stock	8,25,98,603	5,35,59,945
Packing Material Consumed	28,27,57,106	19,60,75,189
Total Rs...	76,36,18,250	43,57,91,835
SCHEDULE - 20 : Changes in Inventories of Finished Goods and WIP		
<u>Opening Stock</u>		
Finished Stock	10,00,66,659	6,10,05,080
Goods in Transit	73,41,883	12,27,130
	10,74,08,543	6,22,32,210
<u>Closing Stock</u>		
Finished Stock	11,63,47,971	10,00,66,659
Goods in Transit	1,39,00,064	73,41,883
	13,02,48,035	10,74,08,543
Total Rs...	-2,28,39,493	-4,51,76,333

for Chairman

for Director

for Director

for Director




AIMIL PHARMACEUTICALS (INDIA) LIMITED

	YEAR ENDED 31.03.2021	YEAR ENDED 31.03.2020
SCHEDULE - 21 : EMPLOYEE BENEFITS EXPENSE		
(a) Salaries and incentives	83,26,33,462	71,16,95,682
(b) Contributions to -		
(i) Provident fund		
(ii) Superannuation scheme		
(iii) ESI	3,40,31,875	3,41,00,756
(c) Gratuity fund contributions	64,92,166	25,38,716
(d) Social security and other benefit plans		
(e) expense on Employee Stock Option Scheme (ESOP) and Employee Stock Purchase Plan (ESPP),		
(f) Staff welfare expenses	1,58,72,032	1,07,13,631
	88,90,29,534	75,90,48,786
SCHEDULE - 22 : OTHER EXPENSES		
Rent, Rates & Taxes	3,74,84,583	4,30,13,595
Fine & Penalty	15,42,056	0
Postage, Telegram & Telephones	33,31,339	44,44,926
Printing & Stationery	22,14,758	31,02,771
Conference Expenses	55,20,809	1,08,25,451
Electricity & water Expenses	45,45,274	34,15,595
Conveyance	84,02,913	1,42,07,954
Flood loss	4,53,70,980	47,64,047
Charity & Donation	2,76,617	900
Bank Charges	27,45,950	32,60,526
Insurance Charges	41,87,349	15,47,577
Fees & Subscription	13,98,428	10,60,375
Legal & Professional Expenses	1,26,53,107	90,65,124
General Expenses	22,52,773	19,78,508
Diwali Expenses	69,369	39,23,333
Office Repair & Maintenance	51,68,292	43,11,483
Vehicle Running & Maintenance	37,15,302	36,31,645
Payment to Auditors - Audit Fees	16,00,000	16,00,000
- Other Expenses	5,25,200	5,25,200
Security Service Charges	32,98,723	37,60,305
Travelling Expenses	76,21,573	1,67,99,666
Books & Periodicals	5,250	1,18,415
Additional Sales Tax Paid	11,000	2,96,374
Royalty	76,99,325	72,10,416
Advertisement & Publicity	46,36,491	66,25,999
Octroi , Freight & Cartage Outward	7,41,61,991	6,35,57,039
Expiry & Breakages	11,89,73,165	4,37,77,258
Sales Promotion & Selling Expenses	1,46,84,18,996	66,14,31,590
C & F Commission & Expenses	3,17,79,300	3,11,26,835
Sales Incentive	8,68,56,639	7,94,89,509
Freight & Cartage	1,15,62,372	86,12,216
Power & Fuel	5,05,44,500	4,43,80,563
Repair & Maintenance - Machinery	58,41,738	55,16,645
- Buildings	23,73,640	11,70,577
- Others	7,69,106	7,69,269
Other Manufacturing Expenses	41,51,494	49,94,165
Expenses incurred on R & D	2,79,75,371	1,81,35,674
	2,04,96,85,772	1,11,24,51,525
SCHEDULE - 23 : FINANCE COST		
Interest Expenses	11,03,54,433	11,27,68,718
Other Borrowing Costs	-	-
Applicable net gain/loss on foreign currency transactions and translation	-	-
	11,03,54,433	11,27,68,718

For Chairman

For Director

For Director



**AIMIL PHARMACEUTICALS (INDIA) LIMITED**

2994/4, STREET NO-17, RANJEET NAGAR, NEW DELHI - 110008

CIN - U24231DL1984PLC019461

BALANCE SHEET AS AT 31st MARCH, 2021

Particulars	Amounts in (Rs.)	Amounts in (Rs.)
	2020-21	2019-20
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Income/(Loss) before tax and extraordinary items	3,60,33,909	2,18,82,576
Adjusted for:		
Depreciation	3,63,68,475	3,72,43,019
Other Income - Interest Income	(5,25,388)	(13,02,412)
Provision for Income Tax	(94,88,500)	(60,00,000)
	6,23,88,496	5,18,23,183
Operating Profit/(Loss) before working capital changes Adjusted for:		
Increase/ (Decrease) Accounts Receivable	(2,32,44,352)	1,98,44,127
(Increase)/ Decrease Inventories	(5,43,34,766)	(5,91,07,789)
Increase/ (Decrease) in Loans & Advances	(46,92,158)	(25,03,269)
(Increase)/ Decrease Short-Term Borrowings	1,37,67,017	59,45,695
(Increase)/ Decrease Trade Payables	4,03,89,321	11,39,263
(Increase)/ Decrease in Current Liabilities	3,30,03,554	81,35,612
(Increase)/ Decrease in Provisions	(71,87,314)	(2,42,54,032)
CASH GENERATED FROM OPERATIONS	(22,98,698)	(5,08,00,392)
NET CASH OUTFLOW FROM OPERATING ACTIVITIES	6,00,89,798	10,22,791
B. CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(5,70,15,461)	(2,92,40,084)
Increase in Intangible Assets	-	(1,61,000)
Other Income - Interest Income	5,25,388	13,02,412
NET CASH FLOWS FROM INVESTING ACTIVITIES	(5,64,90,073)	(2,80,98,672)
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Decrease in Long Term in Borrowings	(41,97,387)	3,54,52,301
Redemption of Preference shares	(67,00,000)	
Dividend declared	(18,64,000)	(28,93,440)
NET CASH FROM FINANCING ACTIVITIES	(1,27,61,387)	3,25,58,861
Net (Decrease) Increase in Cash & Cash Equivalents (A+B+C)	(91,61,662)	54,82,980
Cash and cash Equivalents at the beginning of the year	1,57,18,942	1,02,35,963
Cash and Cash Equivalents at the end of the year	65,57,280	1,57,18,942

SIGNIFICANT ACCOUNTING POLICIES

1

ACCOMPANYING NOTES ARE INTEGRAL PART OF FINANCIAL STATEMENTS

2


As Per Our Report of Even Date Attached

Ambani & Associates LLP

Chartered Accountants

FRN - 016923N

Hitesh Ambani
Designated Partner
(MN-506267)



For and on behalf of the Board


Kanwal Kumar Sharma
(Managing Director)

DIN - 00526387
B-34, Surya Enclave, New
Multan Nagar, Delhi-56


Pankaj Marwaha
(Director - Marketing)

DIN - 00526342
1313, Sector-19 B,
Chandigarh-160019


Ram Sawroop Sharma
(Chief Financial Officer)


Gaurav Agarwal
(Company Secretary)

Place: New Delhi

Date: 01st November 2021

UDIN: 21506267AAAAQC3105

Schedule 1: Significant Accounting Policies

(Annexure to and forming part of the Balance Sheet as on 31.03.2021 and Profit & Loss Account for the year ended on that date)

1.01 Basis of preparation

The accounts have been prepared on historical cost convention as a going concern on accrual basis, in accordance with the requirements of the Companies Act, 2013 and in accordance with the accounting principles generally accepted in India, and comply with the accounting standards notified under the Companies (Accounting Standards) Rules, 2006 (as amended), to the extent applicable. Accounting policies have been consistently applied and where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use, such changes are suitably incorporated. The management evaluates all recently issued or revised accounting standards on an ongoing basis.

1.02 Presentation and disclosure of financial statements

The presentation and disclosure of the financial statements have been made in accordance with the revised Schedule VI notified by the Central Government vide notification no. S.O 447(E), dated 28th February 2011 (as amended by notification no. F No. 2/6/2008-CL-V, dated 30th March 2011) which has become effective for accounting periods commencing on or after 1st April 2011. The adoption of revised schedule VI does not impact recognition and measurement principles followed for preparation of financial statements. However, it has significant impact on presentation and disclosures made in the financial statements. The Company has also reclassified the previous year figures in accordance with the requirements applicable in the current year.

1.03 Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in India requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

1.04 Fixed Assets

- a) Tangible assets are stated at their original cost of acquisition including taxes, duties, freight, and other incidental expenses related to acquisition and installation of the concerned assets less accumulated depreciation and impairment losses, if any. Interest and other borrowing costs during construction period to finance qualifying fixed assets are capitalized.
- b) Subsequent expenditure related to an item of tangible asset is added to its book value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance. All other expenses on existing tangible assets, including day to day repair and maintenance expenditure are charged to the statement of profit and loss for the period during which such expenses are incurred.
- c) Preoperative expenditure and trial run expenditure accumulated as capital work in progress is allocated on the basis of prime cost of fixed assets in the year of commencement of commercial production.
- d) Intangible assets are recognized if it is probable that the future economic benefits that are attributable to the asset will flow to the Company and cost of the assets can be measured reliably.

[Signature]

[Signature]

[Signature]

[Signature]



1.05 Depreciation

- a) Depreciation has been provided on Written down value method at the rates and in the manner as prescribed in Schedule II of the Companies Act, 2013 which approximate the useful life of the assets estimated by the management. The residual values and useful life of assets are reviewed and adjusted, if appropriate, at each balance sheet date.
Depreciation on fixed assets added/disposed off during the year is provided on pro-rata basis. Depreciation on assets for a value not exceeding Rs.5000 acquired during the year is provided at the rate of 100%.
- b) The cost and the accumulated depreciation on fixed assets sold or otherwise disposed off are removed from the stated values and resulting gain and losses are recognized in profit and loss account.

1.06 Inventories

- a) Raw materials, components, stores and spares are valued at lower of cost and net realizable value. However, materials and other items held for use in the production of inventories are not written down below cost if the finished products in which they will be incorporated are expected to be sold at or above cost. Cost of raw materials, components and stores and spares is determined on a moving weighted average basis.
- b) Work-in-progress and finished goods are valued at lower of cost and net realizable value. Cost includes direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity. Cost of finished goods includes excise duty and is determined on a weighted average basis.
- c) The stocks of scrap materials have been taken at net realisable value.

1.07 Retirement Benefits

Contributions to defined contribution scheme such as provident fund etc. are charged to profit & loss account as incurred. The company also provides for retirement /Post Retirement benefits in form of gratuity, pensions and medical. Such benefits are recognized as an expense as and when incurred.

1.08 Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the group and the revenue can be reliably measured. Revenue from sales are recognized when significant risks and rewards of ownership of the goods have passed to the buyer which coincides with delivery and are recorded net of returns. Sales are exclusive of sales tax, value added tax & Goods and Service Tax. Sales do not include inter-divisional/Branch transfers.

1.09 Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares. The number of shares and dilutive shares are adjusted by issue of bonus shares, if any.

[Signature]

[Signature]

[Signature]

[Signature]



1.10 Taxes on Income

Tax expense for the year comprises of current tax and deferred tax.

- a) Current tax is determined on the amount of tax payable in respect of taxable income for the period, using the applicable tax rates and tax laws in accordance with the provisions of Income Tax Act 1961.
- b) Deferred tax is recognized, subject to consideration of prudence, on timing differences, being difference between taxable and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is accounted for using the tax rates and laws that have been enacted or substantively enacted as on the Balance Sheet date. Deferred tax assets are recognized only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. At each reporting date, the group re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

1.11 Impairment of assets

The group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an assets or cash-generating unit's (CGU) net selling price and its value in use. The recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining net selling price, recent market transactions are taken into account, if available. If no such transactions can be identified, an appropriate valuation model is used. Impairment losses of continuing operations, including impairment on inventories, are recognized in the statement of profit and loss. After impairment, depreciation is provided on the revised carrying amount of the asset over its remaining useful life.

1.12 Borrowing costs

Borrowing cost includes interest and other costs incurred in connection with the arrangement of borrowings and exchange differences arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the respective asset. All other borrowing costs are expensed in the period they occur.

1.13 Foreign Currency Transaction

Foreign Currency Transaction are recorded in the reporting currency by applying to the foreign currency amount, the exchange rate between the reporting currency and the foreign currency at the date of transaction. Foreign currency monetary items are retranslated using the exchange rate prevailing on the reporting date. Exchange differences arising on the settlement of the monetary items or on reporting such monetary items of the company at the rate different from those at which they were initially recorded during the year or reported in previous year financial statements are recognized as income or expense in the year in which they arise.

[Signature]

[Signature]

[Signature]

[Signature]



1.14 Provisions and Contingent Liabilities

Provisions

A provision is recognized when the group has a present obligation as a result of past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates.

The company has filed a claim of Rs.12,16,00,000 (Rupees Twelve Crore Sixteen lac only) to United India Assurance Co. Ltd. on account of Loss of Stock and Factory Building due to flood at Nalagarh Factory on 17/18 August 2019 and against Rs.12,16,00,000, company have received only 8,04,04,685. Balance Rs.4,11,95,315 was non receivable & booked expenses "Flood Loss" under "Other Expenses". Also the company face another flood in Nalagarh Factory and the company suffer Rs.40,71,299 as flood loss. Rs. 1,04,366 another flood loss in godown at Patna Bihar.

Contingent Liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the group or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability.

- 1.15 Accounting policies not specifically referred to otherwise are in consonance with generally accepted accounting policies.

[Signature]

[Signature]

[Signature]

[Signature]



Schedule 2: Notes to Accounts

(Annexure to and forming part of the balance sheet as on 31.03.2021 and Profit & Loss Account for the year ended on that date)

2.1 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand and short-term investments with an original maturity of three months or less.

2.2 Deferred Tax Liability

	Amount Rs.
W.D.V As per Companies Act, 2013	25,14,16,862
W.D.V As Per Income Tax Act, 1961	23,29,81,356
Difference	1,84,35,506
Deferred Tax Liabilities as on 31.03.2021	47,93,232
Deferred Tax Liabilities as on 31.03.2020	24,25,299
Provision to be made for FY 2020-21	23,67,933

2.3 Auditor's Remuneration consists of followings:

	<u>2020-21</u>	<u>2019-20</u>
Audit Fees	15,00,000	15,00,000
Tax Audit Fees	1,00,000	1,00,000
Other Matters	3,50,000	3,50,000
Other Expenses	<u>1,75,200</u>	<u>1,75,200</u>
TOTAL	21,25,200	21,25,200

2.4 Particulars of Remuneration Paid to Directors

	<u>2020-21</u>	<u>2019-20</u>
Managing Director	36,00,000	36,00,000
Other Directors	<u>84,35,400</u>	<u>84,35,400</u>
TOTAL	1,43,97,600	1,20,35,400

2.5 The Earning Per Share (EPS) comes to Rs. 29.57 per share (Previous year Rs 20.56 per share on 8,17,560 Equity Shares) on 8,17,560 Equity Shares on annual basis.

For and behalf of the Board
Ambani & Associates LLP
Chartered Accountants
FRN-016923N


(Hitesh Ambani)
M.No.- 506267
Designated Partner




Kanwal Kumar Sharma
(Managing Director)


Ram Sawroop Sharma
(Chief Financial Officer)


Pankaj Marwaha
(Director - Marketing)


Gaurav Agarwal
(Company Secretary)

Place: New Delhi
Date: 01.11.2021

Annexure 'A' to Notes to Accounts

Accounting Standard (AS-18) – "Related Party Disclosure"

S.No	Description Of Related Party	Name of Related Party
1	Name of Associate Company	Aimil Marketing Services Pvt. Ltd. Aimil Ayouthveda India Ltd.
2	Key Management Personnel	a. Mr. K. K. Sharma - Managing Director b. Mr. Pankaj Marwaha - Director Marketing c. Mrs. Manjula Sharma - Director d. Mr. Satya Prakash Srivastava - Director e. Mr. Ikshit Sharma - Director
3	Relatives of Key Management Personnel	a. Mr. Sanchit Sharma - Son of Managing Director b. Mrs. Pooja Sharma - Wife of Mr. Ikshit Sharma c. Mrs. Sugandha Marwaha - Wife of Mr. Sanchit Sharma d. Mrs. Priya Marwaha - Wife Of Mr. Pankaj Marwaha e. Mrs. Nitika Kohli - Daughter of MD Sir f. Mrs. Rashmi Srivastava - Wife of Director g. Mrs. Jyotsana Sharma - Daughter of Director h. Mr. Kartik Marwaha - Son of Director i. Mrs Subhash Sharma - Sister of MD Sir

(Figures are in '000)

Particulars	Key Management Personnel		Relatives of KMP	
	31/03/2021	31/03/2020	31/03/2021	31/03/2020
Director's Remuneration				
Mr. K. K. Sharma	3600.00	3600.00		
Mr. Pankaj Marwaha	2400.00	2400.00		
Mrs. Manjula Sharma	3600.00	3600.00		
Dr. Ikshit Sharma	3600.00	3600.00		
Mr. S. P. Srivastava	1197.60	972.60		

Salary				
Mr. Sanchit Sharma			3600.00	3600.00
Mrs. Pooja Sharma			3600.00	3600.00
Mrs. Sugandha Marwaha			3600.00	3600.00
Mrs. Priya Marwaha			961.44	961.44
Mrs. Nitika Kohli			3600.00	3600.00
Mrs. Rashmi Srivastava			786.60	786.60
Mrs. Jyotsana Sharma			319.60	479.40
Mr. Kartik Marwaha			2400.00	2200.00
Mrs. Subhash Sharma			600.00	550.00



[Handwritten signatures and initials]

Mr. Marwaha

More than
37 YEARS OF
HEALTH
CARE

AIMIL

PHARMACEUTICALS (INDIA) LIMITED



REGD. OFFICE

2994/4, Street No. 17, Ranjeet Nagar, New Delhi - 110008

PH. : 66410000, 25703041, FAX : 011-25703064

Web : www.aimilpharmaceuticals.com Mail : corporate@aimilpharmaceuticals.com

MANUFACTURING UNIT-I :

A-13/2, Nariana Industrial Area, Phase-I, New Delhi-110 028, INDIA

MANUFACTURING UNIT-II :

Saini Majra, Ropar Nalagarh Road, Tehsil Nalagarh, Distt. Solan (HP), INDIA